News
1d
Stocktwits on MSNGilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned ExuberantGilead Sciences, Inc. (GILD) witnessed a slew of price target hikes on Friday after the company raised its annual product ...
NasdaqGS:GILD 1 Year Share Price vs Fair Value Explore Gilead Sciences's Fair Values from the Community and ...
Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
1d
GlobalData on MSNGilead’s Yeztugo sales “ahead of expectations” following launchGilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.
The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...
Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the ...
Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...
Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...
Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results